| Exclusion Criteria: | 1) Treatment with systemic cancer therapy (including clarithromycin) or radiotherapy within 30 days before the first dose of study agent
2) Treatment with nitrosoureas within 42 days before the first dose of study agent
3) Major surgery within 30 days before the first dose of study afent or planning to have surgery (except for minor surgical procedures) during the study
4) Received any investigational drug/agent within 30 days or 5 half-lives, whichever is longer
5) Received an allogeneic bone marrow or allogeneic peripheral blood stem cell transplant
6) Has clinically significant residual toxicities associated with prior autologous bone marrow or peripheral blood stem cell transplant
7) Administered platelet transfusion or neutrophil growth factor within 2 weeks prior to the collection of screening hematology laboratory sample
8) Transplanted solid organ with the exception of a corneal transplant (>/= 3 months prior to screening)
9) Received any mAB within 60 days of first dose of study agent
10) Serious concurrent illness (medical or psychiatric), uncontrolled infection, or significant cardiac disease characheterized by significant ischemic coronary disease or congestive heart failure not under medical control, or any uncontrolled medical condition (eg, uncontrolled diabetes), including the presence of clinical laboratory abnormalities, that places the subject at unacceptable risk by participating in the study or confounds the ability to interpret data from the study
11) Prior or concomitant malignancy (other than multiple myeloma) except adequately treated basal cell or squamous cell carcinma of the skin, carcinoma in situ of the cervix, or other cancer for which the subject has been disease-free for >/= 3 years
12) Any other concomitant disease-related treatment such as, immunotherapy, biotherapy, radiotherapy, chemotherapy, investigative therapy, or immunosuppressive therapy/corticoid steroids (other than study specific treatment with dexamethasone. However, physiological low doses of corticosteroids for adrenal insufficiency or occasional pretreatment to prevent allergic reactions (eg, to contrast materials) are allowed.
13) Vaccinated with live, attenuated vaccines within 4 weeks of the first administration of CNTO 328
14) Known to be seropositive for HIV, or active hepatitis A, B or C infection
15) Pregnant or lactating women |